Table 1.

Patient characteristics.

Patient	Preoperative Clinical Stage	Staging Post-Cystectomy	Gender	Age	NAC/noNAC	Number of Cycles	Response	Additional Information
1 †#¤	cT2N0M0,G3 *	pT0N0M0	female	69	NAC	1	CR
2 †¤	cT2N0M0,G3	pT0N0M0	male	39	NAC	4	CR
3 †	cT2N0M0,G3	pT0N0M0	male	66	NAC	3	CR	Prostatic cancer Gleason score (3 + 4 = 7)
4 †	cT2N0M0,G3	pT0N0M0	female	79	NAC	3	CR
5 †	cT2N0M0,G3	pT0N0M0	female	77	noNAC	0	/
6 †	cT2N0M0,G3	pT0N0M0	male	76	NAC	3	CR	Prostatic cancer Gleason score (3 + 3 = 6)
7 †	cT1N0M0,G3	pT0N0M0	male	57	noNAC	0	/	Prostatic cancer Gleason score (3 + 3 = 6)
8 #§	cT2N0M0,G3	pT0N0M0	male	73	NAC	3	CR
9 §	cT2N0M0,G2	pT0N0M0	female	67	NAC	3	CR
10 §	cT2N0M0,G3	pT0N0M0	male	83	noNAC	0	/

CR = complete response; SD = stable disease; * = in addition to the solid tumour, the patient also had concomitant CIS (cancer in situ); † = mass spectrometry; # = electron microscopy; ¤ = flow cytometry; § = nanoparticle tracking analysis.